Diana del Carmen Martínez-Méndez

Ms. Diana del Carmen Martínez-Méndez


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
DMDiana del Carmen Martínez-Méndez
Diana del Carmen Martínez-Méndez
María de la Luz Sanchez-MundoMaría de la Luz Sanchez-Mundo
María de la Luz Sanchez-Mundo
MTMaria del Rocio Thompson-Bonilla
Maria del Rocio Thompson-Bonilla
LALuis Marat Alvarez-Salas
Luis Marat Alvarez-Salas
VGVíctor Hugo Rosales García
Víctor Hugo Rosales García
MJMaria Jaramillo-Flores
Maria Jaramillo-Flores
Breast cancer is a serious public health problem worldwide. Although current treatments with drugs such as cisplatin and paclitaxel are effective, they are associated with severe adverse effects and the development of drug resistance, which has prompted the search for new therapeutic strategies. In this context, the present study evaluated the anticancer activity of the ethanolic extract of Tabernaemontana catharinensis (EET) on the breast cancer cell lines MCF-7 (hormone-sensitive) and MDA-MB-231 (triple-negative) using 2D and 3D models. The results showed that EET significantly reduced cell viability in both lines, with IC50 values of 83.06 µg/mL (MCF-7) and 8.3 µg/mL (MDA-MB-231) in 2D and 499.3 µg/mL and 280 µg/mL, respectively, in 3D. In addition, treatment with EET caused cell cycle arrest in the G1 phase, reduced CDK4 activity by 58% and ALDH3A1 activity by 32%, and increased levels of the tumor suppressor protein p53. Significant induction of apoptosis was also observed, evidenced by the activation of caspases -3/7, -8, and -9, along with a decrease in intracellular ATP levels (37% in MCF-7 and 90% in MDA-MB-231), suggesting mitochondrial dysfunction. Finally, EET showed the ability to inhibit cell invasion. Taken together, these results indicate that the ethanolic extract of Tabernaemontana catharinensis has potent antiproliferative, proapoptotic, and antimetastatic activity in breast cancer cells, in both two-dimensional and three-dimensional models. Its effect on various key molecular pathways and its ability to enhance the action of conventional chemotherapeutic agents position it as a promising adjuvant agent in the treatment of breast cancer.

Verified
Journal Article
Open access
PDF file
DMDiana del Carmen Martínez-Méndez
Diana del Carmen Martínez-Méndez
María de la Luz Sanchez-MundoMaría de la Luz Sanchez-Mundo
María de la Luz Sanchez-Mundo
LLLaura Adriana Ortiz Leon
Laura Adriana Ortiz Leon
LALuis Marat Alvarez-Salas
Luis Marat Alvarez-Salas
VGVíctor Hugo Rosales García
Víctor Hugo Rosales García
MJMaria Jaramillo-Flores
Maria Jaramillo-Flores
Breast cancer is a disease with a high incidence and mortality rate worldwide. There is a growing interest in the search for alternative treatments with a good cytotoxic effect but fewer adverse effects, because paclitaxel and cis-platinum treatments present severe adverse effects. The aim of this study was evaluating the antitumor activity of ethyl acetate extract of Ballota hirsuta Benth (EAB) in breast cancer cell lines. The IC50 of EAB is 49.3 μg/mL and 3.7 μg/mL in 2D and 375 μg/mL and 135 μg/mL in 3D in the MCF-7 and MDA-MB-231 cell lines, respectively. It arrested the cell cycle in the G1 phase and decreased CDK4 activity by 86%, increasing the p53 protein levels. During the in silico analysis, the compounds interacted with the IGF-R1, CDK1, CDK2, TNFR1, MLKL, MMP2, MMP9, E-cadherin and N-cadherin proteins, which are involved in necroptosis, invasion and the cell cycle. It decreased the ATP levels in 3D by 87% at 600 μg/mL in MCF-7 and 99% at 250 μg/mL in MDA-MB-231; induced apoptosis by increasing the activity of caspases-3/7, -8 and -9; inhibited invasion and enhanced the effect of cisplatin and paclitaxel in combination with EAB. The results show the antitumor potential of EAB as a possible adjuvant in breast cancer therapy.